SÉOUL, Corée du Sud, 12 mars 2024 /PRNewswire/ — ImmunAbs, une société de biotechnologie de pointe axée sur le développement de nouveaux traitements aux anticorps, a annoncé aujourd’hui la réussite de l’essai clinique de phase 1 pour IM-101. L’IM-101 est un anticorps monoclonal humanisé…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.